Grade My Investments
HomeFree Stock Grades › AVLN

Avalyn Pharma Inc. Common Stock (AVLN) Stock Grade

AVLN · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$1.2B
P/E Ratio
Revenue Growth (YoY)
0.0%
Net Margin
0.0%
Return on Equity
35.7%
Dividend Yield
None

About Avalyn Pharma Inc. Common Stock's fundamentals

Avalyn Pharma is a $1.2 billion market cap pharmaceutical company with flat year-over-year revenue growth of 0.0% and a net margin of 0.0%, reflecting recent losses reported in its latest annual statement. Despite the unprofitable position, the company shows a return on equity of 35.7%, indicating efficient use of shareholder capital relative to earnings. The company does not currently pay a dividend and lacks a meaningful P/E ratio given its loss-making status.

Track AVLN free — no credit card required. Live grade + monthly AI report →